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 Pancreatic ductal adenocarcinoma (PDAC) is a devastating disease that is almost 
uniformly lethal within the first year of diagnosis and is the fourth leading cause of 
cancer deaths in the United States.  Activating mutations in the KRAS protooncogene are 
found in nearly all human PDAC cases as well as in early putative PDAC precursor 
lesions, pancreatic intraepithelial neoplasias (PanINs).  Modeling of PDAC has been 
achieved through expression of an activated Kras allele in mouse pancreas that results in 
PanINs similar to those found in humans.  PanINs develop focally, however, despite 
ubiquitous expression of mutant Kras suggesting that other factors must be involved in 
Kras-induced PanIN formation.  Due to ubiquitous expression of mutant Kras in the 
pancreas, it is unknown which cell type, or types, can contribute to PanINs.  This thesis 
aims to understand the cellular events that lead to Kras-induced PanIN formation, and to 
identify the cellular origin of PDAC.  We find that mature acinar cells of the adult 
pancreas are competent to form PanIN lesions following Kras activation, and this process 
is dramatically accelerated by co-activation of the Notch signaling pathway, which 
antagonizes differentiation during pancreas development, but is largely inactive in the 
adult.  Lineage tracing indicates that Kras/Notch co-activation drives rapid acinar-to-
ductal metaplasia (ADM) during which acinar cells take on a duct-like phenotype, 
providing a mechanism by which acinar cells can serve as the origin of a “ductal” tumor.  
iv 
During ADM, acinar cells lose expression of Ptf1a, a transcription factor that is 
considered the master regulator of acinar cell identity.  To test the requirement for Notch 
in PanIN initiation we deleted the key Notch mediator RbpJ.  Surprisingly, we found that 
loss of RbpJ resulted in an increase in Kras-induced PanIN formation.  In the pancreas, 
however, RbpJ is part of the Ptf1a complex and we suspect that loss of RbpJ could alter 
Ptf1a complex function and perturb acinar cell differentiation, which could allow for 
Kras to drive PanIN formation.  We formally tested whether loss of Ptf1a would allow for 
increased Kras-driven PanIN formation and found that, in the presence of activated Kras, 
Ptf1a null acinar cells rapidly formed PanINs. Expression loss of key differentiation 
factors resulting in ADM may in fact be the initial step towards Kras induced 
tumorigenesis.  ADM is similarly seen during acute pancreatitis, although, ultimately, 
acinar differentiation is restored during the regeneration process.  We find that inducing 
pancreatitis in animals harboring active Kras mutations results in rapid and robust PanIN 
initiation.  Together these studies suggest that perturbation of acinar differentiation 
produces susceptibility to Kras-induced PDAC initiation.
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 The pancreas can be considered two organs in one, as it performs two distinct 
biological functions: an exocrine function carried out by acinar cells, which produce and 
secrete digestive enzymes that are channeled to the intestine through a highly branched 
ductal network facilitating food digestion; and an endocrine function that regulates blood 
glucose levels through the action of cells found in the islets of Lengerhans.  Islets are 
comprised of multiple endocrine cell types with insulin secreting β-cells being the 
majority, followed by glucagon-producing α-cells.  Less numerous cell types include 
somatistatin-producing δ-cells, pancreatic polypeptide-producing PP-cells, and ghrelin 
producing ε-cells.  Though the mature pancreas is comprised of a diverse array of cell 
types, they all arise from a common multipotent progenitor pool (Murtaugh, 2007).   
Pancreatic specification occurs at mouse embryonic day 8.5 (E8.5) from two 
strips of foregut endoderm expressing the homeobox transcription factor Pdx1 
(Pancreatic and duodenal homeobox 1)(Ohlsson et al., 1993). These two strips thicken 
and evaginate from the gut tube to form the dorsal and ventral pancreatic buds. These 
proliferate, fuse, undergo a branching morphogenesis, and differentiate into all three 
mature cell types: acinar, duct, and islet (Gu et al., 2002).  From a broad Pdx1-expressing 
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domain, it is thought that expression of the basic helix-loop-helix transcription factor 
Ptf1a-p48 (Pancreas specific transcription factor 1a) specifies pancreatic fate over 
stomach, duodenum, and bile duct, which also arise from Pdx1 expressing endoderm 
(Kawaguchi et al., 2002).  Both Pdx1 and Ptf1a are required for pancreatic specification, 
and lineage tracing studies show that progenitors expressing either factor can give rise to 
all mature cell types (Gu et al., 2002; Jonsson et al., 1994; Kawaguchi et al., 2002; Krapp 
et al., 1998).  While Pdx1 and Ptf1a are expressed broadly during early pancreatic 
development, Pdx1 expression is maintained only in mature β-cells, and expression of 
Ptf1a is maintained only in adult acinar cells. 
Each “organ” within the pancreas is associated with a devastating human disease.  
Autoimmune destruction of β-cells causes insulin deficiency and type-1 diabetes, while 
the exocrine pancreas is the likely origin of pancreatic ductal adenocarcinoma (PDAC), 
the fourth-leading cause of cancer deaths in the United States and the focus of my thesis. 
 
Pancreatic ductal adenocarcinoma 
 Pancreatic ductal adenocarcinoma (PDAC) is an almost uniformly fatal disease 
with over 43,000 diagnoses projected for 2010 (Jemal et al.).  A dismal 5-year survival 
rate of  <5% can be attributed to the lack of early diagnostic methods, such that patients 
present with advanced and often metastatic disease, an innate aggressiveness of the 
malignancy, and robust chemo-resistance.  The current chemotherapy regime is 
gemcitabine, which prolongs a median survival rate of about 6 months by only a matter 
of weeks.  Surgical resection represents the only potentially curative therapy for PDAC, 
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although it extends mean survival to about 15 months and a mere 15% of patients are 
candidates for resection (Han et al., 2006). 
 One of the strongest risk factors for developing PDAC is familial chronic 
pancreatitis, caused by mutations in the Trypsin1 gene (PRSS1) (Lowenfels et al., 1997).  
These individuals have a 40% chance of developing PDAC by age 70, which is an 80-
fold increased risk over the general population.  Other hereditary syndromes such as 
Peutz-Jeghers (Giardiello et al., 2000), hereditary non-polyposis colorectal cancer 
syndrome (Yamamoto et al., 2001), and familial atypical multiple melanoma syndrome 
(Bartsch et al., 2002) are associated with increased risk of PDAC, although these 
syndromes confer increased risk of numerous malignancies.  Family history of PDAC 
also factors into one’s own risk, as those with a single first degree relative with PDAC 
have a 2.3-fold increased risk, and this risk increases with the number of first degree 
relatives with PDAC (Amundadottir et al., 2004; Klein et al., 2004).  Nevertheless, 
additional susceptibility loci have yet to be identified.  The leading preventable cause of 
PDAC is cigarette smoking, which doubles the chance of getting PDAC (Lowenfels and 
Maisonneuve, 2006). 
 An almost universal somatic mutation found in human PDAC is an activating 
mutation of the KRAS proto-oncogene (Almoguera et al., 1988; Hruban et al., 2001b).  
KRAS is part of the RAS family of small GTPases that mediate growth factor signaling 
from receptor tyrosine kinases through multiple effector pathways including the RAF-
mitogen-activated kinase (MAPK), phosphoinositide-3-kinase (PI3K), and Ral GDS 
pathways (Campbell et al., 1998; Malumbres and Barbacid, 2003).  When is bound to 
GTP, RAS activates downstream targets, while GDP-bound RAS is inactive. The 
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intrinsic GTPase activity of RAS terminates signaling by converting GTP to GDP, and 
this activity, is enhanced through interaction with a GTPase activating protein (GAP). 
Reactivation occurs through interaction with a guanine nucleotide exchange factor (GEF) 
that exchanges GDP for GTP.  KRAS mutations found in human cancers, most 
commonly replacing glycine at codon 12 with aspartate, valine, or arginine, abolish the 
GTPase activity of KRAS and leave it permanently GTP-bound and constitutively active 
(Hezel et al., 2006).  
PDAC has been proposed to arise from one of three putative precursor lesions, 
mucinous cystic neoplasm (MCN), intraductal papillary mucinous neoplasm (IPMN), and 
pancreatic intraepithelial neoplasm (PanIN), with the last being the most commonly 
observed in humans and therefore the best characterized (Hezel et al., 2006).  PanINs are 
classified into three stages, PanIN-1-3, with PanIN-3 considered carcinoma in situ 
(Hruban et al., 2001a).  A characteristic PanIN-1 lesion is comprised of a ring of cells 
with tall columnar cytoplasm with basally located nuclei.  Progression to later stage 
PanINs is accompanied by increasing dysplasia, nuclear atypia, and accumulation of 
additional mutations, ultimately resulting in metastatic adenocarcinoma.  Not only are 
activating mutations in KRAS the most prevalent found in PDAC, they are also found in 
the earliest stage PanIN lesions (Moskaluk et al., 1997) suggesting that they may 
represent an initiating event.  While mutations in KRAS happen early and may be 
responsible for initiation of the disease, loss-of-function mutations in tumor suppressor 
genes such as p16 and p53 are found in more advanced PanINs, suggesting a role in 
disease progression and providing the basis for a PanIN-to-PDAC progression model 






Figure 1.1:  Morphologic and genetic progression model of pancreatic 
tumorigenesis.  Progression from histologically normal epithelium (at left) to metastatic 
adenocarcinoma (at right) is associated with increasing dysplasia and accumulation of 
genetic alterations.  The cell of origin for PDAC remains controversial and this model 
depicts two potential candidates, amylase expressing acinar cells and hes1 expressing 
centroacinar cells.  Early stage PanIN-1 lesions have a characteristic tall columnar 
cytoplasm and basally located nuclei and harbor mutations in the KRAS2 proto-oncogene 
and exhibit telomere shortening.  Progression to PanIN-2 and PanIN-3 lesions is 
associated with increased dysplasia and nuclear atypia and mutations in key tumor 
suppressor pathways.  Mutations in p16 are often found in PanIN-2 lesions whereas 
mutations in TP53 and SMAD4 are associated with PanIN-3 suggesting that these 
mutations are driving progression from one PanIN stage to the next, ultimately resulting 
in metastatic disease.  
  6 
Mouse models of PDAC 
 
 With the prevalence of activating mutations in KRAS found in PDAC and early 
PanINs, efforts have been made to model PDAC in the mouse through pancreas specific 
expression of mutant Kras alleles.  Initial studies used tissue specific promoters to drive 
expression of an activated KrasG12D or similar KrasG12V allele.  Expression of KrasG12D 
from the acinar cell specific Elastase1 promoter (Elastase1-KrasG12D) yielded tumors of 
mixed acinar and ductal phenotype but did not produce PanINs or PDAC (Grippo et al., 
2003).  A similar attempt was made using the duct specific Cytokeratin-19 (CK19) 
promoter to drive expression of KrasG12V (CK19-KrasG12V), however this approach did 
not produce any significant phenotype (Brembeck et al., 2003), putting into question 
whether PDAC actually arises from pancreatic duct cells. 
 A breakthrough in PDAC mouse modeling was achieved with the development an 
inducible Kraslox-stop-lox-G12D (KrasLSL-G12D) allele targeted to the endogenous Kras locus 
(Hingorani et al., 2003).  In the absence of Cre recombinase, this allele is not transcribed, 
while expression of Cre from a tissue or cell type-specific promoter will excise the “stop” 
sequence and induce heritable transcription of activated KrasG12D. When pancreatic 
progenitor cell-specific Pdx1-Cre or Ptf1aCre driver lines were used to activate expression 
of KrasLSL-G12D, mice developed focal PanIN lesions that progressed through all PanIN 
stages and, with advanced age, sporadically evolved into PDAC (Hingorani et al., 2003).  
This was the first model that accurately recapitulated the human disease from PanIN to 
PDAC.  Subsequent studies combined this model with mutation of the p53 and p16Ink4a 
tumor suppressors, which are commonly inactivated or mutated in late stage PanINs and 
PDAC, and showed that loss of tumor suppressor function permitted rapid PanIN-to-
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PDAC progression (Aguirre et al., 2003; Bardeesy et al., 2006a; Hingorani et al., 2005).  
Additionally, activating KrasLSL-G12D expression while inhibiting the TGF-β signaling 
pathway, through deletion of Smad4 (Bardeesy et al., 2006b; Izeradjene et al., 2007; 
Kojima et al., 2007) or the type II Tgfβ receptor (Tgfbr2) (Ijichi et al., 2006), resulted in 
PDAC development.  In these models, however, the initial neoplasms observed are not 
PanINs, but IPMNs and MCNs, providing evidence that these lesions should also be 
considered bona fide PDAC precursor.   
Although these drivers used Pdx1Cre or Ptf1aCre to drive ubiquitous expression of 
KrasLSL-G12D in the pancreas, PanINs and PDAC formed only focally, suggesting that 
KrasG12D cannot drive tumorigenesis alone.  Various signaling pathways are aberrantly 
activated in PanINs, including Hedgehog and Notch, which could collaborate with 
KrasG12D to promote tumorigenesis (Hingorani et al., 2003; Thayer et al., 2003).  Notch is 
of particular interest and will be discussed more below.   
While these models have provided a mouse model of human pancreatic cancer 
that faithfully recapitulates PanIN and PDAC development, the use of pan-pancreatic Cre 
drivers precluded the ability to determine which adult cell type is the origin of PDAC.  
Later studies, including our own, have shed light on this question and will be discussed in 
the subsequent chapters as they relate to the work presented in this thesis.  I will discuss 
now, however, the possible candidates and the rationale for consideration as possible 





Tumor cell of origin 
 As the name implies, PDAC has been thought to arise from pancreatic duct cells 
because PDAC and PanINs have a ductal morphology and express ductal markers like 
CK19 and Mucin1.  Early studies tested this by targeting KrasG12V expression to duct cells 
using the Cytokeratin-19 promoter (CK19-KrasG12DV), although this did not result in any 
neoplastic phenotype (Brembeck et al., 2003).  While this suggests that duct cells may 
not be the cell of origin for PDAC, duct cells have not been specifically tested in the 
KrasLSL-G12D model due to the unavailability, until recently (Solar et al., 2009), of a duct 
specific Cre driver.  Whether expression of activated KrasG12D in adult duct cells will 
result in PanIN or PDAC development remains to be seen. Ongoing efforts have instead 
focused on two other cell types of the exocrine pancreas: centroacinar cells (CACs) and 
acinar cells. 
 Resident stem or progenitor cells are likely candidates for the origin of cancers 
because they are often long-lived, providing ample time to accumulate mutations that 
could result in tumor initiation.  To date, no stem cells have been identified in the 
pancreas but CACs are a candidate.  CACs are found at the junction of the ductal network 
and an acinus (Zelander et al., 1962).  They have been thought to maintain stem-like 
characteristic due to their maintenance of active Notch signaling (Kopinke et al., 2011; 
Miyamoto et al., 2003; Stanger et al., 2005), which inhibits the differentiation of 
progenitor cells during pancreas development (Apelqvist et al., 1999; Esni et al., 2004; 
Hald et al., 2003; Jensen et al., 2000; Murtaugh et al., 2003).  Recently, CACs have been 
shown to give rise to acinar and islet cells in vitro (Rovira et al.), although this does not 
appear to occur in vivo (Kopinke et al., 2011; Kopp et al., 2011; Solar et al., 2009).  
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CACs have been shown to give rise to invasive adenocarcinoma following the deletion of 
Pten, a key negative regulator of PI3K signaling although the initial lesions that arise in 
this model are reminiscent of IPMNs rather than PanINs (Stanger et al., 2005).  In 
humans, activating PI3K mutations have been found in IPMN but not PanIN or PDAC 
(Schonleben et al., 2006) suggesting that tumorigenesis from different cellular 
compartments may require different oncogenic stimuli and result in different types of 
neoplastic lesions.   
 Acinar cells make up the bulk of the pancreas and therefore this compartment 
could be considered the largest target for tumor-inducing mutations.  Early transgenic 
experiments used the Elastase1 promoter to drive acinar specific expression of different 
oncogenes, including H-Ras, SV40 T-antigen, and cMyc, and demonstrated their ability to 
undergo transformation (Ornitz et al., 1987; Quaife et al., 1987; Sandgren et al., 1991).   
Interestingly, expression of cMyc produced tumors of mixed acinar/ductal phenotype 
suggesting that acinar cells could assume a ductal phenotype when transformed 
(Sandgren et al., 1991).  Later experiments targeted expression of an activated KrasG12D 
allele to acinar cells by transgenic expression from the Elastase1 promoter (Elastase1- 
KrasG12D) or knocking it into the acinar specific Mist locus (Mist1KrasG12D) (Grippo et al., 
2003; Tuveson et al., 2006).  Both of these approaches also produced tumors of a mixed 
acinar/ductal phenotype, further suggesting that acinar cells could serve as the cell of 
origin for duct-like PanIN lesions and PDAC.  It should be noted, however, that none of 
these studies addressed the ability of endogenously-expressed mutant Kras to induce 
ductal lesions from acinar cells, which was one goal of my thesis research.  
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Acinar cell metaplasia 
 As described above, several early acinar cell oncogenesis models produced 
tumors of mixed acinar/ductal phenotype, suggesting that acinar cells can take on ductal 
characteristics.   This process has since been termed acinar-to-ductal metaplasia (ADM) 
and has been shown to occur in other settings, such as following acute pancreatic injury, 
and exposure of cultured acinar cells to the EGF receptor ligand TGF-α (Jensen et al., 
2005; Lardon and Bouwens, 2005; Means et al., 2005; Miyamoto et al., 2003).  While the 
pancreas is normally a quite static organ with very little cell turnover, it possesses a 
robust ability to regenerate following injury.  Experimental pancreatitis, induced by the 
cholecystokinin analogue caerulein, causes widespread and rapid acinar cell necrosis and 
apoptosis.  Those acinar cells that survive undergo ADM and form abnormal tubular 
structures with characteristics of duct cells (Elsasser et al., 1986; Hruban et al., 2006; 
Jensen et al., 2005).  These metaplastic acini activate embryonic progenitor genes, such 
as Pdx1, and embryonic signaling pathways, such as Notch, and proliferate (Jensen et al., 
2005).  The metaplasia resolves with the re-differentiation of acinar cells and a fully 
regenerated organ within seven days.  Isolated acinar cells placed in 3D culture also 
undergo ADM following treatment with TGF-α (Means et al., 2005; Miyamoto et al., 
2003).  This process requires Notch signaling, and active Notch signaling is sufficient to 
induce ADM of acinar cells in vitro (Miyamoto et al., 2003).  Furthermore, Notch 
signaling is not only reactivated but plays a critical role in pancreatic regeneration 
(Siveke et al., 2008). As chronic pancreatitis is a risk factor for PDAC and active Notch 
signaling is seen in PanINs and PDAC, the reactivation of Notch signaling may 
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contribute to pancreatic tumorigenesis by inducing the conversion of acinar cells to a 
duct-like phenotype, which may represent the initial event in pancreatic tumorigenesis. 
 
Notch signaling 
 The mammalian Notch gene family includes four paralogs, Notch1-4, encoding 
transmembrane receptors that are activated by extracellular Delta and Jagged family 
ligands on neighboring cells.  Following receptor-ligand interaction, Notch is cleaved 
first by an ADAM metalloprotease to release the extracellular portion of Notch, and 
second by the intramembranous gamma (γ)-secretase complex, which releases the Notch 
intracellular domain (NICD) (Kopan and Ilagan, 2009).  The NICD then translocates to 
the nucleus where it binds RbpJκ/CSL/Su(H) (henceforth RbpJ), converting RbpJ from a 
transcriptional repressor to an activator, and transcriptional co-activators such as 
Mastermind-like (MAML) to activate downstream target genes of the Hes and Hey 
families of bHLH transcriptional repressors (Fig. 1.2)  (Kageyama et al., 2007; Kopan 
and Ilagan, 2009). 
During pancreatic development, Notch signaling is active in the progenitor 
population and acts to keep them in an undifferentiated state (Apelqvist et al., 1999; Esni 
et al., 2004; Hald et al., 2003; Jensen et al., 2000; Kopinke et al., 2011; Murtaugh et al., 
2003).  Loss of the key Notch target gene Hes1 results in premature endocrine 
differentiation, as Hes1 normally represses expression of the pro-endocrine transcription 
factor Neurog3 (Apelqvist et al., 1999; Jensen et al., 2000; Lee et al., 2001).  Similarly, 
deletion of the Notch mediator RbpJ early in pancreas development also results in 




Figure 1.2: Notch signaling.  Notch is a transmembrane receptor that is activated by 
extracellular ligands of the Delta and Jagged families. Following receptor ligand 
interaction Notch is cleaved first by an ADAM metalloprotease and second by γ-
secretase, which releases the Notch intracellular domain (NotchIC).  NotchIC then 
translocates to the nucleus where it interacts with RbpJ and Mastermind-like (MAML) to 
activate transcription of downstream target genes of the Hes and Hey families.  
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day later in development affects only exocrine cell development (Fujikura et al., 2007; 
Nakhai et al., 2008), although this phenotype may be due to a Notch independent role of 
RbpJ, which will be discussed at length in Chapter Four.   Conversely, constitutive 
activation of Notch signaling in progenitor cells traps them in an undifferentiated state 
(Esni et al., 2004; Hald et al., 2003; Murtaugh et al., 2003).  As mentioned above, Notch 
is largely inactive in the adult pancreas except in centroacinar cells and occasional duct 
cells (Kopinke and Murtaugh; Miyamoto et al., 2003).  Importantly, however, Notch 
signaling is reactivated in human PanINs and PDAC, evidenced by expression of Notch 
ligands and target genes, including HES1 (Miyamoto et al., 2003).  Similar activation of 
the Notch signaling pathway is seen in PanIN lesions of mouse models (Hingorani et al., 
2003).  Activation of Notch in PanINs suggests that it could play an initiating role with 
activated Kras.  Consistent with the role of Notch in development, it could act through 




 Pancreatic cancer is a deadly disease that that has an extremely poor prognosis 
once diagnosed.  While many malignancies have seen clinical advancements due to basic 
research over the last few decades, pancreatic cancer has not.  This lack of progress is 
partly due to the aggressive nature of the disease and our inability to detect it early 
enough, when surgery can offer the only curative treatment.  Activating mutations in the 
KRAS proto-oncogene are found in almost all PDAC cases, and in early PanIN lesions.  
Conditional expression of an activated KrasG12D allele in mouse pancreatic progenitor 
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cells, which give rise to all adult cell types, produced a model closely recapitulating the 
human disease.  These mice begin to develop PanIN lesions within a few months of birth 
and over time all three PanIN stages are seen.  These mice can, with advanced age, 
progress to metastatic disease at a low frequency.  Advanced human PanINs and PDAC 
are associated with mutation or silencing of tumor suppressor genes such as p16 and p53, 
and combined expression of KrasG12D with p16 or p53 loss-of-function in mouse drives 
rapid advancement from PanIN to metastatic PDAC.  These models leave open two key 
questions.  First, what is the cell of origin of this disease?  These early studies utilized 
Cre drivers that are active during development and induce recombination in the 
progenitor population which gives rise to all adult cell types, leaving it unclear which cell 
type actually gives rise to PanIN lesions.  Second, what limits the ability of activated 
Kras to drive tumorigenesis?  Following recombination during development, KrasG12D is 
expressed by almost all cells in the organ, however, PanINs develop only focally and 
over time, suggesting that other factors are restraining the ability of KrasG12D to drive 
transformation on its own.  This thesis focuses on these two fundamental questions. 
 Acinar cells have been shown have tumorigenic potential in over-expression 
studies, whereas duct cells have not.  Further, acinar cells are able to undergo ADM, in 
which they lose acinar characteristic and become duct-like, providing a potential 
explanation of how acinar cells can give rise to ductal lesions.  Notch signaling has been 
found to be necessary and sufficient for ADM of cultured acinar cells, and is upregulated 
in metaplastic acini following acute pancreatitis.  While Notch signaling is mostly silent 
in adult pancreas, it is reactivated in PanIN and PDAC, suggesting that it may play a role 
in Kras-driven tumorigenesis.  This role may be to antagonize acinar cell differentiation 
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programs, as Notch does in embryonic pancreatic progenitor cells, providing a permissive 
cellular environment for activated Kras to drive PanIN initiation.  Likewise, other insults 
to acinar cell differentiation, such as acute pancreatitis, may also provide the proper 
tumorigenic environment for activated Kras.  This thesis will test the competency of adult 
acinar cells to give rise to PanINs, and investigate the role of Notch signaling in 
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 Notch signaling is activated in human pancreatic ductal adenocarcinoma (PDAC) 
and its putative precursor lesions, termed pancreatic intraepithelial neoplasia (PanIN) 
(Miyamoto et al., 2003), and mouse models of PDAC show similar activation (Hingorani 
et al., 2003).  Notch signaling plays a critical role during pancreatic development, 
keeping progenitor cells in an undifferentiated state, but is largely inactive in the adult 
pancreas (Murtaugh et al., 2003)}(Apelqvist et al., 1999; Esni et al., 2004; Hald et al., 
2003; Jensen et al., 2000), suggesting that reactivation of Notch signaling may play a role 
in tumorigenesis.  Indeed, our previous study demonstrated that transgenic activation of 
Notch signaling together with expression of activated Kras (KrasG12D) in adult acinar 
cells caused increased PanIN initiation and rapid PanIN progression (De La O et al., 
2008).   
While ectopic Notch signaling can synergize with Kras to induce PanIN 
formation, it remains unclear if activation of endogenous Notch signaling is required for 
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Kras-induced PanIN initiation or progression. Recent studies have attempted to answer 
these questions.  First, in tumor-prone mice combining KrasG12D activation with p53 loss-
of-function, long-term treatment with a gamma-secretase inhibitor, inhibiting Notch 
receptor activation, completely prevented progression to PDAC and to some extent 
PanIN initiation (Plentz et al., 2009).  Second, activation of KrasG12D and concomitant 
deletion of Notch2 resulted in low-grade PanIN (PanIN1) formation but inhibited 
progression to higher grade PanINs (PanIN2 and PanIN3), while deletion of Notch1 had 
no effect suggesting that Notch2 function is required for PanIN progression (Mazur et 
al.).  It should be noted that another group deleted Notch1 in a KrasG12D background and 
observed increased tumor incidence and progression (Hanlon et al.).  This discrepancy 
could reflect inherent differences in Notch1 and Notch2 function, or could be due to the 
timing at which recombination took place, since these two studies used different Cre 
drivers. While these studies indicate that Notch signaling, in particular Notch2, may be 
required for PanIN progression, and hint at a role for Notch in PanIN initiation, a 
requirement for Notch signaling in PanIN initiation remains unclear.  
Notch is activated following interaction with cell surface ligands of the Delta and 
Jagged families.  Notch then undergoes a two cleavage events, the second of which is 
mediated by gamma-secretase and releases the Notch intracellular domain (NICD), which 
translocates to the nucleus and binds RbpJκ/CSL/Su(H) (henceforth (RbpJ) (Kopan and 
Ilagan, 2009).  RbpJ binds to TC-box motifs of TTTCCA and, in the absence of a Notch 
signal, acts as a transcriptional repressor. Together with NICD, however, RbpJ can form 
a ternary complex with the transcriptional co-activator Mastermind-like (MAML), which 
mediates transcription of downstream target genes, including the bHLH transcriptional 
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repressors of the Hes and Hey families (Kageyama et al., 2007; Kopan and Ilagan, 2009). 
Genetic analysis in the fly indentified Su(H) as the downstream mediator of Notch 
signaling and mammalian analysis has mostly supported this (Fortini and Artavanis-
Tsakonas, 1994).   
As the mammalian genome encodes four Notch receptors, but a single RbpJ 
homolog, loss-of-function studies targeting RbpJ should disable all Notch signaling 
without issues of receptor redundancy.  Studies in the mouse using a conditional loss-of-
function RbpJ allele (RbpJlox) (Han et al., 2002) have been mostly congruent with this 
model.  Deletion of RbpJ in the intestine causes loss of Hes1 expression and precocious 
goblet cells differentiation, phenotypes that are also seen following pharmacological 
inhibition of Notch activation with a gamma-secretase inhibitor (van Es et al., 2005).  In 
the skin, Notch regulates melanoblast maintenance and loss of RbpJ causes these cells to 
undergo apoptosis, which can be recued by targeted Hes1 overexpression in RbpJ knock-
out (KO) melanoblasts (Moriyama et al., 2006).  These and other studies indicate that 
deletion of RbpJ appears to be an effective method of inhibiting Notch signaling.    
In the pancreas, active Notch signaling is present in early progenitor cells, as 
evidenced by expression of the Notch target gene Hes1, and acts to maintain their 
progenitor state (Apelqvist et al., 1999; Esni et al., 2004; Hald et al., 2003; Jensen et al., 
2000; Murtaugh et al., 2003).  Ectopic activation of Notch in pancreatic progenitor cells 
inhibits their differentiation, trapping them in a progenitor state (Esni et al., 2004; Hald et 
al., 2003; Murtaugh et al., 2003).  Accordingly, Hes1 knock-out (KO) mice exhibit 
premature differentiation of pancreatic progenitor cells resulting in a hypoplastic organ, 
suggesting that Hes1 is the key effector of Notch signaling during pancreatic 
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development (Jensen et al., 2000).  Deletion of RbpJ early in pancreatic development, 
using Pdx1Cre, causes premature differentiation and hypoplasia similar to Hes1 KO 
mice, providing confirmatory evidence that Notch acts early in pancreas development to 
antagonize differentiation and maintain multipotency of progenitors (Fujikura et al., 
2006).  Interestingly, deletion of RbpJ one day later in pancreas development, using 
Ptf1aCre, does not result in premature differentiation of progenitors, but instead delays 
acinar cell differentiation until late fetal development, although compensatory growth 
after birth results in a normal and functional adult organ (Fujikura et al., 2007).  While it 
would be easy to conclude from these RbpJ deletion studies that Notch plays one role 
early, to maintain progenitors, and later acts to promote acinar cell differentiation, the 
situation is complicated by the recently discovered Notch-independent role of RbpJ in the 
Ptf1a complex.  Ptf1a is a basic helix-loop-helix (bHLH) transcription factor that is 
initially expressed in all pancreatic progenitors and later becomes restricted to mature 
acinar cells, where it drives acinar specific gene transcription (Masui et al., 2007).  Ptf1a 
forms heterotrimeric complexes with a common E-protein, such as HEB, and either RbpJ 
during early development, to promote pancreas specification and acinar differentiation, or 
its paralog RbpJ-like (RbpL) in mature acinar cells, to maintain acinar specific gene 
expression (Beres et al., 2006) (Masui et al., 2010).    Whereas, the phenotype of early 
RbpJ deletion is likely due to Notch inhibition as it mimics Hes KO mice, the observed 
defect in acinar differentiation of later RbpJ deletion may not reflect a defect in Notch 
signaling, but rather the absence of RbpJ from the Ptf1a complex.  The late rescue of 
acinar differentiation may be due to RbpL upregulation, which then likely drives 
compensatory acinar growth (Beres et al., 2006; Masui et al., 2010).   
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 In the current study, we aimed to assess whether activation of endogenous Notch 
signaling is required for Kras-driven PanIN formation. We used a floxed allele of RbpJ 
(RbpJlox ) to effectively and conditionally inhibit Notch signaling.  With the adult acinar 
specific ElaCreERT, we activated expression of KrasG12D while deleting RbpJ to 
determine if KrasG12D-expressing acinar cells are able to form PanINs in the absence of 
Notch signaling.  Because RbpJ does not appear to play a role in the adult Ptf1a complex, 
RbpJ deletion should disrupt Notch-RbpJ signaling only and not Ptf1a function. 
 
Materials and Methods 
 
Mice 
ElaCreERT (Murtaugh et al., 2005; Stanger et al., 2005; Strobel et al., 2007), 
KrasLSL-G12D (Hingorani et al., 2003), and RbpJlox (Han et al., 2002) mice have been 
described previously.  Animals were genotyped by PCR using DNA from tail biopsies.  
Cre-negative littermates served as wild type controls. Tamoxifen (TM) was dissolved in 
corn oil and administered by oral gavage.  All experiments were carried out according to 
institutional guidelines. 
 
Tissue processing and histology  
Following euthanasia, pancreata were dissected, cut into small fragments and 
fixed overnight in zinc buffered formalin at room temperature for wax sectioning, or 1-3 
hours in 4% paraformaldehyde (PFA) at 4°C for frozen sectioning.  Formalin fixed tissue 
was dehydrated through an ethanol series, cleared in xylene, then washed and embedded 
in paraffin wax.  Tissue fixed in PFA was washed with PBS, placed in 30% sucrose (w/v) 
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overnight at 4°C, then embedded in OCT medium.  Wax and frozen sections were cut at 
6 µm and 8 µm thickness respectively. Primary antibodies included rabbit anti-Hes1 (gift 
from Nadean Brown 1:1000) and rabbit anti-Neomycin phosphotransferase II 
(USBiological 1:2000), and secondary antibodies were purchased from Jackson 
Immunoresearch.  Paraffin sections were subjected to high temperature antigen retrieval 
(Vector Unmasking Solution) before adding primary antibody. Vectastain reagents and 
Vector diaminobenzidine substrate were used for immunohistochemistry. 
 
Lesion scoring.  As previously described (De La O et al., 2008), two independent dorsal 
and one ventral fragment were paraffin-embedded and sectioned from each pancreas.  
After H&E staining of a single section from each fragment, and 
photomicrography/photomerging (Adobe Photoshop), the area of the section was 
determined with ImageJ software (NIH).  PanIN lesions were then scored under the 
microscope, and the PanIN initiation index was defined as the number of lesions per cm2 
averaged across the three sections analyzed from each mouse. 
 
RNA isolation and quantitative PCR 
Six week old mice were administered two doses of 10 mg of TM, spaced one day apart, 
and RNA was harvested 7 days following the last TM administration, at which point no 
gross morphological changes are apparent in any genotype.  RNA was isolated from 
approximately half the dorsal pancreas using guanidinium isothiocyanate (MacDonald et 
al., 1987).  One microgram of total RNA was reverse transcribed using Superscript III 
(Invitrogen) according to the manufacturers protocol, and quantitative PCR was 
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performed using Power SYBR Green master mix (Applied Biosystems) on an ABI 
7900HT.  All quantification was done using the ΔΔCt method using Gapdh as a reference 
gene (Schmittgen and Livak, 2008).  All primers were selected from Primer Bank 
(Spandidos et al., 2010), except for the RbpJ exon 5-6 spanning primers, which were 
designed with Primer3 (www.ncbi.nlm.nih.gov/tools/primer-blast).  Primer sequences are 














Table 4.1. Primer sequences used for realtime PCR.   
Gene Forward primer Reverse primer 
Product size 
(bp) 
Gapdh AGGTCGGTGTGAACGGATTTG TGTAGACCATGTAGTTGAGGTCA 123 
Hes1 CCAGCCAGTGTCAACACGA AATGCCGGGAGCTATCTTTCT 166 
RbpJ  TGGTGTGTTCCTCAGCAAGCGG CCCCACTGTTGTGAACTGGCGT 195 
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Results 
Conditional deletion of RbpJ leads to increased Kras-driven PanIN formation.
 To test the hypothesis that activation of endogenous Notch signaling is necessary 
for KrasG12D-induced transformation, we used the conditional RbpJ lox allele to generate 
RbpJlox/lox;KrasLSL-G12D;ElaCreERT mice, along with RbpJlox/+;KrasLSL-G12D;ElaCreERT 
mice as controls.  We administered 5 mg of TM to 6-week-old mice and chased these 
animals for 4.5 months, which is adequate time for KrasG12D-expressing cells acinar cells 
to form PanINs in otherwise wild-type mice (De La O et al., 2008). As expected 
RbpJlox/+;KrasLSL-G12D;ElaCreERT pancreata contained dispersed focal PanINs after the 
chase period (Fig. 4.1B and C).  Surprisingly, however, RbpJlox/lox;KrasLSL-
G12D;ElaCreERT  pancreata had numerous and large PanIN lesions throughout the tissue 
(Fig. 4.1D-F).  Loss of RbpJ alone did not yield any histological phenotype (Fig. 4.1A). 
The density of PanIN lesions was significantly higher in RbpJlox/lox;KrasLSL-
G12D;ElaCreERT than in RbpJlox/+;KrasLSL-G12D;ElaCreERT pancreata (Fig. 4.2) indicating 
that the loss of RbpJ actually sensitized acinar cells to KrasG12D rather than make them 
refractory. 
To ensure that we were indeed inducing recombination of the RbpJlox alleles, we 
stained paraffin sections for the neomycin resistance enzyme Neomycin 
phosphotransferase 2 (Npt2), as the neoR cassette is still present between the loxP sites in  
this RbpJ allele (Fig. 4.3A).  Therefore, cells that underwent recombination would be 
negative for Npt2, whereas cells that retained an intact RbpJ locus would stain positive 
for Npt2.  In control RbpJlox/lox pancreata, all cells were positive for Npt2 (Fig. 4.3B),   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Figure 4.1:  Conditional deletion of RbpJ in adult acinar cells results in increased 
Kras induced PanIN formation.  Representative H&E stained paraffin sections of the 
indicated genotypes.  Mice were pulsed with 5 mg of TM at 6 weeks of age and chased 
for 4.5 months, allowing ample time for PanIN formation.  Deletion of RbpJ from acinar 
cells causes no histological phenotype (A).  RbpJlox/+;KrasLSL-G12D;ElaCreERT pancreata 
results in focal Kras induced PanIN formation (B and C), however, RbpJlox/lox; KrasLSL-











Figure 4.2: Quantification of PanINs shows significantly more PanINs formed from 
RbpJ null acinar cells.  Stripchart of PanIN initiation indices (PanIN lesions/cm2) for 
individual TM-treated RbpJlx/+;KrasG12D;ElaCreERT (RbpJlx/+) and 
RbpJlx/lx;KrasG12D;ElaCreERT (RbpJlx/lx) mice pulsed with 5 mg of TM at 6-weeks of age 
and chased for 4.5 months.  RbpJlx/lx mice have significantly more PanINs than RbpJlx/+ 
mice (p< 0.01). 
  46 
while in RbpJlox/lox;ElaCreERT pancreata we observed mosaic staining for Npt2  in acinar 
cells indicating the cells that did and did not undergo recombination (Fig. 4.3C).  The 
PanINs found in RbpJlox/lox;KrasLSL-G12D;ElaCreERT pancreas were indeed negative for 
Npt2 (Fig. 3D-F), indicating that the PanINs formed from RbpJ null acinar cells and that 
the sensitizing effect of RbpJ loss was likely to be cell autonomous.      
 
Hes1 is activated in RbpJ null acinar cells 
RbpJ acts as a transcriptional repressor when not bound to activated Notch and its 
deletion could cause derepression of its target genes, thus indirectly mimicking an active 
Notch signal.  Indeed, several targets of the Drosophila RbpJ homolog, Su(H), are 
derepressed in Su(H) mutants (Koelzer and Klein, 2003; Koelzer and Klein, 2006; 
Tapanes-Castillo and Baylies, 2004).  We therefore stained for the Notch target gene 
Hes1, which is known to be expressed in PanINs of mice and men.  In control pancreata 
we observed faint Hes1 staining in duct and centroacinar cells (Fig. 4.4A), and, as 
expected, PanINs from RbpJlox/+;KrasLSL-G12D;ElaCreERT pancreata were strongly 
positive for Hes1 (Fig. 4.4B).  Surprisingly, PanINs from RbpJlox/lox; KrasLSL-
G12D;ElaCreERT pancreata were also positive for Hes1 (Fig. 4.4C).  Therefore, despite 
being RbpJ deficient, the Notch target gene Hes1 was upregulated or derepressed in 
PanIN lesions.  
To further examine the possibility of Hes1 derepression we administered a higher 








Figure 4.3: PanINs arising in RbpJlox/lox pancreata have undergone recombination.  
(A) The RbpJlox allele places loxP sites around exons 6 and 7, which encode the DNA 
binding domain, resulting in a non-functional protein following Cre-mediated 
recombination.  Also within the loxP sites is the neoR cassette that will be removed 
following recombination. (B-F) Adult (6-week old) mice of the indicated genotypes were 
pulsed with TM and analyzed 4.5 months later.  Positive staining for neomycin 
phosphotransferase II (Npt2) (brown) indicates cells that have not undergone 
recombination.  Control pancreata, lacking Cre, stain ubiquitously for Npt2 (A), while 
RbpJlox/lox;ElaCreERT pancreata show mosaic staining indicating the subset of cells that 
has undergone recombination (B).  PanINs from RbpJlox/lox;KrasLSL-G12D;ElaCreERT 
pancreata are negative for neo indicating that they did, in fact, undergo recombination 
and that the phenotype is cell autonomous (C-E).  Panel (E) includes a PanIN that has 
incorporated cells that did not undergo complete RbpJ recombination (arrowhead), 
confirming that we can distinguish between cells that retain or have lost Npt2 expression. 
















Figure 4.4: PanINs are positive for Hes1.   PanINs arising in mice treated with TM at 6 
weeks of age and chased for 4.5 months were stained for the Notch target gene Hes1.  
Control pancreata are mostly devoid of Hes1 staining except for faint staining in 
occasional duct (arrowheads) and centroacinar cells (A).  PanINs arising in 
RbpJlox/+;KrasLSL-G12D;ElaCreERT pancreata are positive for Hes1 (arrowheads) as 
expected  (B), however PanINs arising from RbpJlox/lox;KrasLSL-G12D;ElaCreERT 
pancreata also express Hes1 (arrowheads)despite loss of RbpJ  (C).  Original 
magnification: 400X. 
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recombination, to adult  RbpJlox/+;ElaCreERT and RbpJlox/lox;ElaCreERT in the presence 
or absence of KrasLSL-G12D.   These mice were harvested 7 days after the last TM dose, a 
chase time that would allow us to catch early transcriptional changes preceding any 
morphological abnormalities. To confirm that we had deleted RbpJ, we performed qRT-
PCR with RbpJlox specific primers and observed reduced expression approximately two-
fold in RbpJlox/lox; KrasLSL-G12D;ElaCreERT and RbpJlox/lox; ElaCreERT pancreata relative 
to controls (Fig. 4.5). Correspondingly, Hes1 expression was increased approximately 2-
2.5-fold in RbpJlox/lox; KrasLSL-G12D;ElaCreERT and RbpJlox/lox;ElaCreERT pancreata (Fig. 
4.5), indicating derepression of Hes1 following the loss of RbpJ.  Expression of Hes1, 
even at low levels, might mimic low level Notch signaling and thus be able to synergize 












Figure 4.5: Hes1 expression is upregulated in RbpJ null pancreata.  Adult (6-week 
old) mice were pulsed with two 10 mg doses of TM spaced one day apart and RNA was 
extracted 7 days after the last injection to catch initial transcriptional changes, by 
quantitative RT-PCR.  Using primers specific to the unrecombined allele, we confirmed 
that RbpJ expression is significantly reduced in RbpJlox/lox;ElaCreERT pancreata 
irrespective of KrasG12D expression.  Correspondingly, Hes1 expression is significantly 
increased in pancreata that have deleted RbpJ, again irrespective of KrasG12D expression.  




 Notch signaling is reactivated during pancreatic tumorigenesis, and is sufficient to 
synergize with activated Kras to drive PanIN initiation (De La O et al., 2008; Miyamoto 
et al., 2003).  Here, we sought to determine if activation of Notch signaling is required for 
Kras driven PanIN formation.  To this end, we deleted RbpJ, which mediates all Notch 
signaling, while activating expression of KrasG12D.  If Notch activation were necessary 
for PanIN initiation, we would not expect to see PanINs forming from RbpJ null acinar 
cells.  We found, however, that the deletion of RbpJ resulted in a significant increase in 
Kras-driven PanIN formation.  Further, we found that these PanINs upregulated the 
Notch target gene Hes1, despite having deleted RbpJ, and that deletion of RbpJ in normal 
acinar cells resulted in increased Hes1 expression.  We must therefore conclude that the 
loss of RbpJ promotes Kras-induced PanIN formation rather than impairs it.   
 In the absence of a Notch signal, RbpJ acts as a transcriptional repressor.  
Therefore, the loss of RbpJ may not be inhibiting Notch signaling, rather its absence as a 
transcriptional repressor could result in the derepression of target genes, mimicking 
active Notch signaling.  One or more of these target genes, expressed at a low level, is 
then able to synergize with KrasG12D in promoting PanIN formation.  Work in the 
Drosophila wing disc has shown that Su(H) mutants exhibit a less severe phenotype than 
Notch mutants, due to a transient de-repression of the Notch target gene vestigial (vg) 
(Koelzer and Klein, 2006).  Low level expression of vg in Su(H) mutants, caused by the 
absence of Su(H) mediated repression, partially rescues the wing phenotype seen in 
Notch mutants.  This phenomenon was also observed when comparing Notch and 
Presenilin (Psn) mutants to Su(H) mutants during Drosophila mesodermal patterning and 
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bristle development, respectively (Koelzer and Klein, 2003; Tapanes-Castillo and 
Baylies, 2004). Low level Hes1 expression could mimic active Notch signaling, although 
likely not to the extent achieved from the Rosa26NIC allele used previously (De La O et 
al., 2008), as neither the phenotype of RbpJ deletion and Kras activation, nor the extent 
of Hes1 upregulation, are as dramatic as those observed with NotchIC and Kras co-
activation.  Perhaps only a subset of cells can increase Hes1 expression to a critical level 
that renders them susceptible to KrasG12D expression.  In addition to derepression, it is 
possible that removing RbpJ from the promoter region of Hes1 could open it up to other 
potential activating signals, such as Sonic hedgehog (SHH), which can activate Hes1 by 
Notch and RbpJ independent mechanisms (Ingram et al., 2008).  
 Lastly, RbpJ has a Notch independent function in the pancreas, which is to 
complex with the transcription factor Ptf1a/p48 in pancreatic progenitor cells and drive 
pancreas specific gene expression (Beres et al., 2006; Masui et al., 2007).  Ptf1a is 
expressed in all pancreatic progenitor cells but its expression is retained only in 
differentiated acinar cells, where it complexes with the RbpJ paralog RbpJ-like (RbpL) to 
drive acinar specific gene expression and auto-regulation of Ptf1a and RbpL. (Masui et 
al., 2007; Masui et al., 2008).  Although it is thought that RbpL completely replaces RbpJ 
in the Ptf1a complex upon acinar differentiation, loss of RbpL does not show a dramatic 
acinar phenotype, suggesting that RbpJ may play more of a role in the Ptf1a complex 
than initially thought (Masui et al., 2010).  
  As Ptf1a is thought to be the master regulator of acinar cell fate, deletion of RbpJ 
could be detrimental to acinar cell differentiation by its absence from the Ptf1a complex. 
Recently it was found that RbpJ titration away from Ptf1a by active Notch signaling in 
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pancreatic endocrine progenitors was necessary to drive endocrine fate (Cras-Meneur et 
al., 2001).  Our observed Notch-Kras synergy (De La O et al., 2008) could reflect the 
titration of RbpJ away from Ptf1a.  In this way, genetic deletion of RbpJ could mimic 
Notch activation.  Nonetheless, the phenotype seen here is less severe than that seen with 
active Notch, suggesting that Notch-Kras synergy involves mechanisms beyond simple 
RbpJ titration. 
 Studies of RbpJ/RbpL-Ptf1a interactions identified a mutant, Ptf1aW298A , that is 
unable to bind RbpJ but retains its ability to interact with RbpL (Beres et al., 2006). 
Ptf1aW298A/W298A mice exhibit pancreatic agenesis, like Ptf1a nulls, suggesting that early 
Ptf1a functions are mediated by interacting with RbpJ (Masui et al., 2007). We could use 
this allele in conjunction with a conditional floxed Ptf1a allele to generate Ptf1aW298A/lox; 
KrasLSL-G12D;ElaCreERT mice, which would develop normally due the floxed Ptf1a 
allele.  Administering TM to adult mice would result in acinar cells that express only the 
Ptf1aW298A allele in conjunction with KrasG12D.  If we observed increased PanIN 
initiation, similar to RbpJlox/lox; KrasLSL-G12D;ElaCreERT pancreata, we could conclude 
that the RbpJ deletion phenotype is due to the loss of RbpJ in the Ptf1a complex.  If it is 
not similar, derepression of Hes1 could be the mechanism. 
 Our results are consistent with Hes1 being the key mediator of Notch signaling 
during Kras-driven PanIN formation, as appears to be the case during embryogenesis 
(Jensen et al., 2000). The best way to test this is with conditional Hes1 gain-of-function 
and loss-of-function alleles, the latter of which would bypass developmental defects of 
Hes1 null embryos (Jensen et al., 2000). Utilizing a floxed Hes1 (Hes1lox) allele 
(Imayoshi et al., 2008) one could simultaneously delete Hes1 and activate KrasG12D, 
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testing the requirement for Hes1 in Kras-driven tumorigenesis.  Conversely, a conditional 
gain-of-function allele, which does not currently exist, would test the sufficiency of Hes1 
to synergize with activated Kras inducing PanIN formation.  Generating a Hes1 gain-of-
function allele could be accomplished by targeting the Hes1 coding sequence to the 
ubiquitously expressed Rosa26 locus.  Placing the Hes1 coding sequence down stream of 
a floxed “stop” sequence would allow for conditional activation.  One would have to be 
aware of potential effects of Hes1 overexpression that confound the analysis.   
 The requirement for endogenous Notch activation in Kras-driven PanIN 
formation still remains to be definitively elucidated.  We have shown that in the absence 
of RbpJ, Hes1, and possibly other Notch target genes, are derepressed, which could 
mimic a low level active Notch signal and synergize with activated Kras.  We also 
hypothesize that RbpJ is playing more of role in the adult Ptf1a complex than originally 
thought, and that the deletion of RbpJ could lead to a dysfunctional Ptf1a complex, which 
could affect the differentiation status of acinar cells enabling activated Kras to drive 
tumorigenesis.  Additional experiments outlined here could test these hypotheses and 
further our understanding of how the differentiation status of the acinar cell plays a role 
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ACINAR CELL DIFFERENTIATION STATUS DETERMINES SUSCEPTIBILITY   
 





  Pancreatic ductal adenocarcinoma (PDAC) and PanINs are similar to duct cells in 
their morphology and histology, which led to the hypothesis that PDAC is of ductal 
origin.  Recent studies, however, have shown that acinar cells are competent to form 
PanINs suggesting that PDAC could arise from acinar cells.   PanIN formation from 
acinar cells involves acinar-to-ductal metaplasia (ADM), in which acinar cells undergo 
morphological changes, downregulate acinar marker expression, and upregulate ductal 
markers.  In the presence of KrasG12D, this process culminates in the formation of duct-
like PanINs, in which all traces of acinar origin are lost (De La O et al., 2008). Fully 
differentiated acinar cells can lose their differentiation status and become duct-like under 
other circumstances, including exposure to TGF-α in vivo and in vitro, and during 
pancreatitis (Blaine et al.; Elsasser et al., 1986; Means et al., 2005; Miyamoto et al., 
2003; Strobel et al., 2007).   Importantly, Notch signaling is upregulated during 
pancreatitis in vivo, and is necessary and sufficient for TGF-α induced ADM in vitro 
positioning, this pathway as a key mediator metaplasia (Jensen et al., 2005; Miyamoto et 
al., 2003).  Notch signaling plays a critical role during pancreatic development but is 
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largely inactive in adult tissue (Apelqvist et al., 1999; Esni et al., 2004; Hald et al., 2003; 
Jensen et al., 2000; Murtaugh et al., 2003).  Notch is reactivated in human and mouse 
PanINs and PDAC (Hingorani et al., 2003; Maitra and Hruban, 2008; Miyamoto et al., 
2003) and we have shown that forced activation of Notch dramatically accelerates ADM 
and PanIN formation induced by activated Kras (De La O et al., 2008).  These results 
suggest that an initial step towards PanIN formation is the loss of acinar cell identity and 
metaplasia, a process in which Notch may play a central role.    
 During the transition toward PanIN formation, acinar cells lose expression of the 
basic helix-loop-helix transcription factor Ptf1a, considered to be a “master regulator of 
acinar cell differentiation (De La O et al., 2008; Rose et al., 2001). Ptf1a is expressed in 
early pancreatic progenitors, which give rise to all three adult pancreas lineages, and is 
required for acinar cell differentiation (Kawaguchi et al., 2002; Krapp et al., 1998).  In 
the mature organ, Ptf1a expression is restricted to acinar cells (Masui et al., 2007), where 
it helps drive acinar specific gene transcription.  Ptf1a forms a heterotrimeric complex 
with a common E-protein, such as HEB, and either RbpJ/Su(H) or its paralog RbpJ-like 
(RbpL) (Beres et al., 2006). Critical to Ptf1a expression during development and in 
differentiated acinar cells is a 2.3-kb enhancer region that contains two binding sites for 
the Ptf1a complex allowing for autoregulation of expression (Masui et al., 2008).  
Downregulation of this critical acinar transcription factor may be essential for acinar cell 
metaplasia and Kras-induced PanIN formation.   
Taken together, the reactivation of the Notch signaling pathway seen in PanINs 
(Miyamoto et al., 2003), the dramatic synergy seen between Notch and Kras activation 
(De La O et al., 2008), and the developmental role of Notch in inhibiting acinar 
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differentiation (Murtaugh et al., 2003), suggest that Notch may promote metaplasia and 
PanIN formation by antagonizing differentiation.   Indeed, active Notch signaling has 
been shown to antagonize Ptf1a function by titrating RbpJ away from the Ptf1a complex, 
favoring endocrine differentiation (Cras-Meneur et al., 2009).  Additionally, ectopic and 
constitutive Notch activation in pancreas progenitor cells inhibits Ptf1a expression and 
differentiation of the progenitors (Schaffer et al.).  Conversely, Hes1 null embryos 
display ectopic Ptf1a expression (Jensen et al., 2000).  It is unknown, however, if active 
Notch signaling can antagonize Ptf1a function and/or expression when activated in fully 
differentiated acinar cells, and if Ptf1a antagonism is important in the process of 
metaplasia and PanIN formation, or just an observed side-affect.  We hypothesize that the 
loss of Ptf1a will sensitize acinar cells to Kras-induced PanIN formation, and that 
Notch/Kras synergy is mediated by Notch antagonism of Ptf1a creating a permissive 
environment that allows for Kras-driven transformation (De La O et al., 2008).   
 In this study we demonstrate that loss of Ptf1a with concomitant activation of 
KrasG12D results in rapid acinar-to-ductal metaplasia and PanIN formation from adult 
acinar cells, and that active Notch signaling antagonizes Ptf1a expression.  We further 
show that a partial reduction of Ptf1a expression, through loss of a single copy, creates a 
permissive environment for Kras induced PanIN formation.   These results indicate that 
perturbation of acinar cell differentiation creates a permissive environment for Kras 
induced PanIN formation, and support acinar-to-ductal metaplasia as representing an 




Materials and Methods 
Mice 
ElaCreERT (Murtaugh et al., 2005; Stanger et al., 2005; Strobel et al., 2007), 
KrasG12D (Hingorani et al., 2003), and Rosa26NIC (Murtaugh et al., 2003) mice have been 
described previously.  Ptf1aCreERT and Ptf1alox mice have not been published and were 
generous gifts from Christopher Wright (Vanderbilt University).  In Ptf1aCreERT the 
CreERT coding region is placed into the first exon of Ptf1a by a knock-in/knock-out 
approach that removes normal Ptf1a function.  In Ptf1alox, loxP sites flank exons 1 and 2 
and following recombination result in a null allele.  Animals were genotyped by PCR 
using DNA from tail biopsy.  As neither KrasG12D nor Rosa26NIC are expressed in the 
absence of Cre, Cre-negative littermates served as negative controls. Tamoxifen (TM) 
was dissolved in corn oil and administered by oral gavage.  All experiments were carried 
out according to institutional guidelines. 
 
Tissue processing and histology  
Tissues were processed and stained as described in Chapter 4. 
 
RNA isolation and quantitative PCR 
RNA isolation and quantitative RT-PCR was carried out as described in Chapter 
4.  Primer sequences are listed in Table 5.1. 
 
Cell culture and in vitro reporter assays 
The mouse acinar carcinoma cell line, 266-6 (Ornitz et al., 1987), was obtained 
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form the American Type Culture Collection (cat. # CRL-2151). 266-6 cells were cultured 
on 0.1% gelatin coated tissue culture plates in Dulbecco’s modified Eagle’s medium 
supplemented with 10% fetal bovine serum (Hyclone) and antibiotics and glutamine 
(Invitrogen). pElaIp.luc and Ptf1a enhancer (pElaIp.Ptf1a enh.) luciferase reporter 
plasmids have been previously described (Beres et al., 2006; Masui et al., 2008) and were 
generous gifts from Ray MacDonald (University of Texas Southwestern Medical Center). 
The pElaIp.luc construct has the minimal promoter sequence of Elastase1 linked to the 5’ 
end of the luciferase gene of pGL3-basic (Promega).  The Ptf1a enh construct has the 2.3 
kb autoregulatory enhancer region of Ptf1a cloned upstream of the Elastase1 minimal 
promoter in pElaIp.luc.  Transfections were performed in a 24-well format with 80,000 
cells plated per well, using 200 ng of luciferase reporter plasmid, 10 ng of constitutive 
Renilla luciferase expression vector (phRL-TK) for normalization, 100 ng of each 
expression construct (where appropriate), and up to 600 ng empty vector for a total of 
810 ng of DNA. Plasmids were transfected using 2.4 µl of Lipofectamine 2000 
(Invitrogen) per well and according to the manufacturers protocol.  Luciferase activity 
was assayed 48 hrs post-transfection using the Dual-luciferase reporter assay system 
(Promega) and a GloMAX-20/20n luminometer (Promega).  The Notch1IC expression 
construct has been described previously (Kopan et al., 1996) and was a generous gift 
from Raphael Kopan (Washington University), and the mouse Hes1 expression construct 













Table 5.1. Primer sequences used for realtime PCR.   
 
Gene Forward primer Reverse primer 
Product size 
(bp) 
Gapdh AGGTCGGTGTGAACGGATTTG TGTAGACCATGTAGTTGAGGTCA 123 
Ptf1a TCCCATCCCCTTACTTTGATGA GTAGCAGTATTCGTGTAGCTGG 140 
Ela2 GCCTCAGCAACTATCAGACCT CGACGTTTTGGGAGTTCCAC 129 
Amy2 GCAAGTGGAATGGCGAGAAGA AGCCAACATAAATCCGACAGC 191 
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Results 
Loss of Ptf1a results in rapid KrasG12D driven PanIN formation 
To test the hypothesis that loss of the key acinar transcription factor Ptf1a would 
render adult acinar cells susceptible to KrasG12D expression, we generated 
Ptf1aCreERT/lox;KrasLSL-G12D mice.  In these mice Ptf1a protein expression is driven 
exclusively by the conditional Ptf1alox allele, which can be converted to a null by CreERT 
expressed from Ptf1aCreERT following tamoxifen administration.  We wanted specifically 
to target fully differentiated adult acinar cells; as Ptf1a expression is restricted to acinar 
cells in adult pancreata, we waited until mice were 6-8 weeks of age to induce 
recombination.  
 Following 10mg of TM administration, cohorts of mice were chased for one week 
or one month.  After one month, pancreata of Ptf1aCreERT/lox;KrasLSL-G12D mice were 
extremely hypoplastic and wispy (Fig. 5.1D), unlike the normal plump and opaque 
appearance of pancreata from littermate controls (Fig. 5.1A).  Hematoxylin and eosin 
(H&E) staining of paraffin sections revealed that these pancreata contained numerous 
PanIN lesions and were almost devoid of normal acinar cells (Fig. 5.2D and H).  As 
expected, pancreata of Ptf1aCreERT/+;KrasLSL-G12D mice had a grossly normal pancreas 
(Fig. 5.1C) and only focal PanIN formation (Fig. 5.2C and G).   Somewhat surprisingly, 
given that Ptf1a is considered critical to acinar cell differentiation, Ptf1aCreERT/lox 
pancreata had no gross phenotype (Fig. 5.1B).  Examination of H&E-stained sections, 
however, revealed focal areas of metaplastic acini (Fig. 5.2B and F), which might be 










Figure 5.1:  Deletion of Ptf1a and expression of KrasG12D in adult acinar cells causes 
a gross phenotype.  Representative images of freshly dissected mouse pancreas of the 
indicated genotypes, one month after TM administration.  Normal pancreatic tissue has a 
plump and opaque appearance (A).  Deletion of Ptf1a from acinar cells did not have any 
adverse affects on the gross appearance of the tissue (B).  Expression of KrasG12D in 
acinar cells also did not show a gross phenotype (C).  Expression of KrasG12D and 
deletion of Ptf1a resulted in a small and wispy pancreas.  Abbreviations: dp, dorsal 













Figure 5.2:  Activated Kras drives rapid PanIN formation from Ptf1a deleted acinar 
cells.  Representative H&E stains of paraffin sections from pancreata of the indicated 
genotypes, 30 days following TM administration.  Low magnification images (A-D) 
show the overall histology observed, while higher magnification images (E-H) reveal the 
affected areas.    Normal pancreatic histology is seen in control Ptf1aCreERT/+ pancreata (A 
and E). Ptf1aCreERT/lx pancreata in which Ptf1a has been deleted displayed focal areas of 
acinar cell metaplasia, which could indicate of a loss of acinar cell differentiation (B and 
F).  As expected expression of KrasG12D in a Ptf1a hemizygous background resulted in 
focal PanIN formation (C and G), while expression of KrasLSL in a Ptf1a deleted 
background resulted in almost the entire pancreas being taken over by PanINs and 
infiltrating stroma, leaving very little normal acinar tissue (D and H).  Original 
magnification: A-D 100x; E-H 400x. 
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Due to the severity of the Ptf1aCreERT/lox;KrasLSL-G12D phenotype after only one 
month, we analyzed a cohort of mice one week after TM administration.  We saw no 
gross phenotype in any genotype, however, acinar cell metaplasia and PanINs were  
already observed in Ptf1aCreERT/lox; KrasLSL-G12D mice when analyzed histologically (Fig. 
5.3D and H).  No abnormalities were observed in other genotypes by the one-week chase 
time (Fig. 3). 
 
Active Notch signaling inhibits Ptf1a transcription 
Previously, it was shown that the Notch signaling pathway is active in mouse and 
human PanINs (Hingorani et al., 2003; Miyamoto et al., 2003).  Further, active Notch 
signaling is able to synergize with KrasG12D to drive PanIN initiation from adult acinar 
cells, which involves downregulation of acinar genes including Ptf1a (De La O et al., 
2008).  We hypothesized that Notch contributed to PanIN initiation by antagonizing 
acinar cell differentiation, as Notch prevents progenitor cell differentiation, inhibits Ptf1a 
expression during pancreas development, and is sufficient to induce acinar-to-ductal 
metaplasia of cultured acinar cells (Miyamoto et al., 2003; Murtaugh et al., 2003; 
Schaffer et al.).  Perturbation of acinar cell differentiation may then provide a permissive 
cellular environment for oncogenic Kras to drive transformation.  We therefore examined 
expression of acinar-specific mRNAs in pancreata expressing the conditional Notch1 
gain-of-function transgene, Rosa26Notch1IC-ires-EYFP (Rosa26NIC), in the presence or absence 
of KrasG12D.  To activate these transgenes in adult acinar cells, we used the tamoxifen 
inducible ElaCreERT transgene, in which the Elastase1 promoter drives expression of 















Figure 5.3:  Histological changes in Ptf1aCreERT/lx;KrasLSL pancreata are apparent 
within seven days after TM administration.  Representative H&E stained sections 
from pancreata of the indicated genotypes, seven days following TM administration.  
Seven days following TM administration, areas of acinar cell metaplasia are present in 
Ptf1aCreERT/lx;KrasLSL pancreata; whereas no changes are seen in any other genotype 
within this short chase time.  Original magnification: A-D 100x; E-H 400x. 
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(Murtaugh et al., 2005; Stanger et al., 2005).  Four mice per genotype were given 5 mg of 
TM at 6-8 weeks of age and chased for one week, a time point before gross histological 
changes are observed.  We found that when Notch signaling is activated, either in the 
presence or  
absence of KrasG12D, expression of acinar genes including Ptf1a were reduced (Fig. 5.4).  
This suggested that active Notch signaling did antagonize acinar cell differentiation, 
possibly mediated by a reduction in Ptf1a expression.  Consistent with this, we also saw 
downregulation of the acinar specific genes Elastase2 and Amylase2 (Fig. 5.4).  While 
Ptf1a expression was reduced on average in both Notch and Notch-Kras activation, this 
was not statistically significant (p= 0.052 and p= 0.061 respectively).  Our methodology 
for these experiments uses whole pancreas, and while acinar cells make up the majority 
of the pancreas, only about 50% of acinar cells have undergone recombination.  As a 
result, our ability to assess subtle transcriptional changes in a minority of cells that 
underwent recombination might be limited.  We think that the trend toward reduced Ptf1a 
would be even more pronounced if assayed specifically in cells that underwent 
recombination, and we propose that Notch acts to decrease Ptf1a expression and could 
therefore promote Kras-induced transformation by antagonizing acinar cell 
differentiation.  While Notch activation is necessary and sufficient for ADM in vitro 
(Miyamoto et al., 2003), Rosa26NIC activation in vivo does not result in detectable 
morphological effects in acinar cells without Kras (De La O et al., 2008).  We think 
therefore that Notch may reduce Ptf1a expression to a critical threshold that is permissive 












Figure 5.4:  Notch activation inhibits expression of Ptf1a and acinar specific genes 
independent of KrasG12D expression.  Quantitative RT-PCR results from RNA extracted 
from whole pancreas seven days after TM administration (n=4 per genotype).  Activation 
of Rosa26NIC, independent of Kras genotype, coincided with reduced Ptf1a expression, 
which could affect overall acinar cell differentiation.   In support of this, we also saw 
reduced expression of the acinar specific genes Elastase2 and Amylase2.  (* p< 0.05; ** 
p< 0.01). 
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Notch and its downstream effecter Hes1 inhibit Ptf1a-driven transcriptional 
reporters. 
Due to the difficulty of assaying subtle transcriptional changes when analyzing 
whole pancreata, we used in vitro luciferase reporter assays to determine if Notch can  
affect Ptf1a expression. To evaluate Ptf1a expression, the 2.3 kb Ptf1a autoregulatory 
enhancer region was placed upstream of the Elastase1 minimal promoter and linked to 
luciferase (pElaIp.luc.Ptf1a enh.) (Masui et al., 2008).  The Elastase1 minimal promoter 
inserted upstream of luciferase (pElaIp.luc) was used as a baseline.  We see that in 266-6 
acinar carcinoma cells (Ornitz et al., 1987), which express all necessary components for 
acinar gene transcription, the Ptf1a enh. reporter has 10 fold higher activity than 
pElaIp.luc (Fig. 5A).  However, expression of the Notch1 intracellular domain (NotchIC), 
thus mimicking active Notch signaling, results in a 2-fold reduction in luciferase activity 
(Fig. 5.5A), demonstrating that Notch signaling can negatively regulate Ptf1a expression.   
 The transcriptional repressor Hes1 is a well-characterized Notch target gene, is 
upregulated in the pancreas following transgenic Notch activation, and expressed in 
PanINs and PDAC (De La O et al., 2008; Miyamoto et al., 2003).  During pancreas 
development Hes1 is likely a key mediator of Notch signaling in the progenitor 
population (Jensen et al., 2000).  Prior to pancreatic specification, Hes1 represses Ptf1a 
expression in early foregut endoderm defining the boundaries to the pancreatic domain, 
and loss of Hes1 results in misexpression of Ptf1a in gut and bile duct progenitors fating 
them to become pancreas tissue (Fukuda et al., 2006).  Due to its role as a transcriptional 
repressor and its known role in pancreas development, we tested if Hes1 could mediate 





Figure 5.5:  Expression of the Notch intracellular domain or Hes1 reduces Ptf1a 
reporter activity in 266-6 cells.  The Ptf1a enhancer luciferase reporter (pElaIp.luc.Ptf1a 
enh), which contains the 2.3 kb autoregulatory enhancer region required for Ptf1a 
expression in the pancreas upstream of the minimal promoter of Elastase1 linked to 
luciferase (pElaIp.luc), shows an 8-9-fold higher activity than the minimal pElaIp.luc 
reporter when transfected alone into 266-6 cells (dark grey bars in A and B).  Co-
expression with 100 ng of a construct expressing the Notch intracellular domain to 
activate Notch signaling has no effect on pElaIp.luc activity , while it reduced Ptf1a enh. 
activity approximately 2-fold (light grey bars in A), suggesting that active Notch 
signaling can inhibit Ptf1a expression.  Expression of the Notch target Hes1 (100 ng of 
plasmid) we saw the same 2-fold reduction in Ptf1a enh. activity (light grey bars in B), 
suggesting that Hes1 is mediating Notch’s transcriptional repression of Ptf1a. 
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reduction in Ptf1a enh. reporter activity seen with NotchIC expression (Fig. 5.5B).  This 
suggests that Notch can antagonize Ptf1a expression and this may be through the 
upregulation of Hes1.  
 
Ptf1a haploinsufficiency provides a permissive environment for KrasG12D driven 
PanIN formation 
While complete loss of Ptf1a allowed for rapid Kras induced PanIN formation 
(Fig. 5.1D and H), it remained unclear if simply a reduction in Ptf1a expression would 
provide the same permissive environment for KrasG12D driven PanIN initiation.  To test 
this we bred Ptf1aCreERT into the KrasLSL-G12D;Pdx1Cre background, taking advantage of 
the fact that his allele is null for Ptf1a.  Offspring of this cross this include mice 
hemizygous for Ptf1a while expressing KrasG12D in the pancreas.  Typically, KrasLSL-
G12D;Pdx1Cre mice develop focal PanIN lesions over time while maintaining mostly 
normal histological appearance (Hingorani et al., 2003), which is precisely what we 
observed in 2-3 month old mice (Fig. 5.6A and D). Ptf1a hemizygous KrasLSL-
G12D;Pdx1Cre, mice, however, displayed almost no normal pancreatic histology; rather, 
mutant pancreata are composed almost entirely of PanINs (Fig. 5.6B-C and E-F).  These 
results strongly suggest that a reduction in Ptf1a expression does, in fact, allow for 
oncogenic Kras to induce transformation.  This dramatic phenotype, while informative, is 
complicated by a developmental phenotype, as Ptf1aCreERT; KrasLSL-G12D;Pdx1Cre mice 
were recovered at a lower frequency than Mendelian inheritance would predict (p< 0.05 
by Chi-square).  This was probably due to a severely reduced number of endocrine cells 
in Ptf1aCreERT; KrasLSL-G12D;Pdx1Cre (Fig. 5.7). Within pancreata of KrasLSL-
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G12D;Pdx1Cre mice, islets of various sizes were easily found and distributed throughout 
(Fig. 5.7A), whereas insulin positive cells were difficult to find in Ptf1aCreERT; KrasLSL-
G12D;Pdx1Cre mice, and often presented as scattered single cells or small disorganized 
clumps (Fig. 5.7B).  This experiment should be repeated using an adult acinar specific 
Cre to remove possible developmental effects, and directly test whether genetic reduction 












Figure 5.6:  Ptf1a hemizygous pancreata are highly susceptible to activated Kras. 
Representative H & E stained sections from pancreata of the indicated genotypes, at three 
months of age.  Pdx1Cre;KrasLSL pancreata develop focal PanIN lesions over time, which 
can be observed by at three months of age (A and D).  When these pancreata are also 
hemizygous for Ptf1a, however, almost the entire pancreas is composed of PanINs and 
very little normal tissue can be found (B-C and E-F).  This phenotype appears to be so 
severe that at weaning Pdx1Cre;KrasLSL;Ptf1aCreERT mice are recovered at a less than 















Figure 5.7: Pdx1Cre;KrasLSL;Ptf1aCreERT pancreata are deficient in insulin producing 
β-cells.  Anti-insulin immuno-staining (brown) PdxCre;KrasLSL pancreata reveals β-cells 
contained islets of various sizes and distributed normally throughout the tissue  (A), 
whereas, insulin positive cells are found infrequently and as single cells or small clumps 
(B).  Pdx1Cre;KrasLSL;Ptf1aCreERT mice may therefore have impaired β-cell development 




 In genetic mouse models of PDAC, KrasG12D expression is necessary but not 
sufficient to initiate PanIN formation, as cells expressing KrasG12D do not immediately 
form PanINs.  Rather, PanINs form focally and with time, often despite ubiquitous 
expression of KrasG12D, suggesting that a permissive cellular environment must be 
achieved for PanIN initiation.  Although PanIN lesions possess ductal characteristics, 
increasing evidence suggests that PanINs and resulting PDAC arise from pancreatic 
acinar cells (De La O et al., 2008; Guerra et al., 2007; Habbe et al., 2008). We 
hypothesize that perturbation of acinar differentiation may provide a permissive 
environment that KrasG12D needs to drive transformation.   
Acinar-to-ductal metaplasia appears to be the initial step towards PanIN formation 
from acinar cells.  During this process acinar gene expression is lost, including that of 
Ptf1a, and duct like markers are turned on (De La O et al., 2008; Habbe et al., 2008).  
Ptf1a is a bHLH transcription factor that has been shown to drive acinar specific gene 
expression and is considered a master regulator of acinar cell differentiation (Rose et al., 
2001).  Consistent with this role, the loss of Ptf1a dramatically sensitizes adult acinar 
cells to KrasG12D-driven PanIN formation.  These results support the hypothesis that 
perturbation of acinar cell differentiation may be a prerequisite for KrasG12D 
transformation.   
Notch signaling acts to inhibit progenitor cell differentiation during pancreas 
development, is largely inactive in the adult organ, but is reactivated in human and mouse 
PanINs (Miyamoto et al., 2003; Murtaugh et al., 2003).  It has also recently been shown 
that ectopic Notch activation in pancreatic progenitor cells inhibits Ptf1a expression, 
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which could be the mechanism by which Notch antagonizes differentiation of progenitor 
cells (Schaffer et al., 2010).  Simultaneous activation of Notch signaling and KrasG12D 
expression showed dramatic synergy in PanIN initiation, while activation of Notch alone 
caused no histological phenotype (De La O et al., 2008).  The role of Notch in this 
setting, possibly similar to its role during development, may be to antagonize 
differentiation by repressing Ptf1a expression.  We show that active Notch signaling can 
suppress Ptf1a expression both in vivo and in vitro, and that the Notch effector Hes1 can 
also suppress Ptf1a expression to a similar level in vitro.  Although Ptf1a expression 
appears only reduced, rather than absent, it may fall below a critical threshold, perhaps to 
a level seen during development prior to the super-induction that occurs upon acinar cell 
differentiation (Masui et al., 2008; Zhou et al., 2007).  The reduction could change the 
cellular environment to a less differentiated state that is sensitive to KrasG12D 
transformation.  This could provide a potential mechanism for the observed synergy 
between Notch and Kras, and a physiologically relevant role for the observed active 
Notch signaling in human and mouse PanINs and PDAC. 
Consistent with the notion that a reduction in Ptf1a levels is sufficient to sensitize 
acinar cells to KrasG12D, loss of a single copy of Ptf1a results in a haploinsufficient state 
that is also dramatically sensitive to KrasG12D.  This is likely due to a developmental 
phenotype caused by being hemizygous for Ptf1a.  Surprisingly, however, previous 
studies in which KrasG12D was activated by Ptf1aCre, which is also a Ptf1a null, did not 
see such a dramatic phenotype (Hingorani et al., 2003). Ptf1aCre should induce 
recombination in a similar population of cells as Pdx1Cre, while also having only one 
functional copy of Ptf1a (Kawaguchi et al., 2002). This discrepancy could be due to 
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Ptf1aCre acting slightly later than our Pdx1Cre transgene (Fujikura et al., 2007).  
Additional experimentation, using inducible adult Cre drivers, is needed to determine if a 
genetic reduction in Ptf1a is sufficient to reduce Ptf1a levels enough to sensitize adult 
acinar cells to activated Kras. 
  While aspects of this potential model for pancreatic cancer initiation remain to 
be tested, we have provided evidence that directly perturbing acinar cell differentiation 
by deletion of Ptf1a dramatically sensitizes cells to KrasG12D.  Additionally, active Notch 
signaling causes reduced Ptf1a expression, possibly below a critical threshold that 
normally prevents KrasG12D-driven transformation.  This may be at least part of the 
mechanism for the observed synergy between active Notch and Kras (De La O et al., 
2008).  Taken together, our studies suggest that perturbation of acinar cell differentiation 
by the genetic deletion of Ptf1a or downregulation by active Notch signaling provides the 
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 Pancreatic cancer is a devastating disease that is almost uniformly fatal within a 
year of diagnosis.  Activating mutations in the KRAS proto-oncogene are found in nearly 
all PDAC cases and also in early stage PanIN lesions suggesting it represents an initiating 
mutation.  Mouse modeling of PDAC was achieved through conditional expression of an 
activated KrasG12D allele (KrasLSL-G12D) (Aguirre et al., 2003; Hingorani et al., 2003). 
Pancreas specific expression was accomplished using Cre drivers that induce 
recombination in pancreatic progenitor cells, which results in expression of KrasG12D in 
all mature pancreatic cell types (islet, duct, and acinar).  These mice develop focal PanIN 
lesions within a few months after birth that progress through all PanIN stages and can, 
with advanced age, develop into metastatic PDAC.  This thesis focuses on advancing our 
understanding of PDAC by addressing two fundamental questions left unanswered by 
this initial mouse model: What adult cell type does PDAC originate from; and what limits 
the ability of activated Kras to initiate tumorigenesis on its own? 
 PDAC and PanINs display ductal characteristics, which led to the hypothesis that 
they are derived from transformed duct cells.  Expression of activated KrasG12V from the 
duct specific CK19 promoter, however, did not result in a transformed phenotype 
(Brembeck et al., 2003).  Acinar cells, on the other hand, can be transformed by over-
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expression of various oncogenes from the acinar-specific Elastase1 promoter, including 
KrasG12D, and will produce tumors of a mixed acinar/ductal phenotype (Grippo et al., 
2003).  These studies not only demonstrated the competence of acinar cells to be 
transformed but that they can become duct like in the process.  We therefore 
hypothesized that PDAC could originate from acinar cells.  To test this hypothesis we 
used the tamoxifen-inducible ElaCreERT driver to induce expression of KrasG12D 
specifically in adult acinar cells.  Following recombination, PanINs and areas of acinar-
ductal metaplasia (ADM) that were often associated with PanINs were found, suggesting 
that the initial step to PanIN formation involves ADM.  The PanINs that arise are 
morphologically and histologically indistinguishable from those found in 
PdxCre;KrasLSL-G12D pancreata.  These results demonstrate that acinar cells can serve as 
the origin for PDAC and that they do so by undergoing ADM, which provides a means 
for acinar cells to serve as the origin of ductal lesions.     
A similar study used the acinar specific Mist1CreERT2 and ElastaseCreERT2 drivers 
to induce expression of KrasG12D and found similar results, providing further evidence for 
an acinar origin of PDAC (Habbe et al., 2008).  It should also be noted that a recent study 
suggested that β-cells could serve as the origin for PanIN, after targeting KrasG12D 
expression to insulin positive cells, using RIPCreERTM, and inducing PanIN formation 
(Gidekel Friedlander et al., 2009).  These results are confounded by the fact the 
RIPCreERTM has been described to also induce recombination in acinar cells (Blaine et 
al., 2010), thus the observed PanINs may well be of acinar origin.  Another recent study 
used CK19CreERT to specifically target expression of KrasG12D to duct cells and found that 
only 7/11 KrasLSL-G12D;CK19CreERT contained PanINs and those that did had few of them, 
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4-6 months post TM administration (Ray et al., 2011).  In contrast we found that all 
KrasLSL-G12D;ElaCreERT mice had numerous PanINs as early as 2.5 months post-TM, 
suggesting that if ducts were competent to for PanINs, KrasLSL-G12D;CK19CreERT mice 
should have developed many more PanINs than they did.  CK19CreERT is active in duct 
cells but also hits acinar cells at a low frequency (Means et al., 2008).  It is therefore 
quite likely that rare recombined acinar cells gave rise to the observed PanINs in KrasLSL-
G12D;CK19CreERT mice.  The low frequency overall provides further evidence that duct 
cells do not contribute to PDAC and that acinar cells are a more likely cell of origin.  
Given the evidence for an acinar origin, and because PDAC is a disease with adult onset, 
we propose that activating KrasG12D in adult acinar cells will provide a more 
physiologically relevant model for studying PDAC initiation and progression. Future 
pancreatic cancer studies in the mouse are likely to benefit from the adult acinar models 
that we and others have established.  
Similar to the KrasLSL-G12D;PdxCre model, only a small subset of the acinar cells 
that underwent recombination formed PanINs in our model, while the majority remained 
normal.  Because Notch signaling is reactivated in PanINs and PDAC, and is required for 
ADM in vitro (Miyamoto et al., 2003), we hypothesized that Notch acts to promote 
KrasG12D-driven PanIN formation.  Indeed, we find that we can dramatically enhance 
PanIN formation by exogenous activation of the Notch signaling pathway, demonstrating 
a strong synergy between Notch and Kras.  These PanINs also progress more quickly, as 
more late stage PanINs (PanIN-2-3) are found in Notch/Kras pancreata than Kras alone, 
suggesting that active Notch not only promotes Kras-driven PanIN initiation but also 
PanIN progression.  
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A recent study found that chronic treatment with a γ-secretase inhibitor, to prevent 
Notch activation, inhibited development of metastatic PDAC in mouse models that 
otherwise develop PDAC with 100% penetrance, further suggesting a role for Notch in 
PanIN progression (Plentz et al., 2009).  Deletion of Notch2 but not Notch1 was also 
found to inhibit PanIN progression, suggesting possible Notch homolog specific roles in 
PDAC (Mazur et al., 2010).  Surprisingly, a study by another group found that deletion of 
Notch1 caused increased KrasG12D-driven PanIN formation, suggesting that Notch1 acts 
as tumor suppressor (Hanlon et al., 2010).  This study not only contradicts the former 
study but also our own work showing that Notch1 promotes PanIN formation.  As 
discussed in Chapter 4, this could have been caused by the use of different embryonic Cre 
drivers, active at slightly different stages such that loss of Notch1 early resulted in 
increased PanIN formation whereas loss of Notch1 a day later did not.  Loss of Notch1 
early could result in the upregulation of other Notch receptors to compensate, which 
could synergize with Kras similar to our study.  The cellular need for Notch1 a day later 
may not be as great and thus not result in an upregulation of other Notch receptors.  
Repeating these experiments in an adult acinar cell setting would avoid any possible 
developmental effects and shed light on homolog specific roles for Notch in PanIN 
initiation and/or progression.  Although controversial, ours and other studies suggest a 
role for Notch in PanIN progression, although its requirement for PanIN initiation had not 
been established. 
Notch signaling from all four Notch homologs is mediated through RbpJ (Kopan 
and Ilagan, 2009). To test the requirement for Notch signaling in PanIN initiation and 
avoid any issue of receptor redundancy, we used the deletion of RbpJ.  Deletion of RbpJ 
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and activation of KrasG12D expression in acinar cells resulted in increased, rather than 
decreased PanIN formation.  While this was contrary to what we expected, there are three 
possible explanations to this phenotype.  First, Notch signaling may indeed be acting as a 
tumor suppressor and thus inhibition of Notch would result in increased PanIN formation.  
Second, the Notch target gene Hes1 was found to be upregulated despite the lack of 
RbpJ, suggesting that loss of RbpJ, which normally represses Notch targets in the 
absence of a signal, de-represses the Hes1 locus.  This de-repression could then mimic an 
active Notch signal and synergize with KrasG12D.  The presence of Hes1 in both normal 
PanINs and RbpJ-null PanINs also suggests that this gene could be the key downstream 
target of Notch and play an important role in tumorigenesis.  This role could be to 
antagonize differentiation as it does during pancreas development (Jensen et al., 2000).  
Third, in the pancreas RbpJ has a Notch independent role, as a member of the Ptf1a 
complex (Beres et al., 2006).  During pancreas development, RbpJ complexes with Ptf1a, 
initially to induce transcription of pancreas specific genes, and later to drive expression of 
acinar specific genes (Beres et al., 2006; Masui et al., 2007).  While it is thought that 
RbpL replaces RbpJ in the Ptf1a complex in mature acinar cells, we consider it likely that 
RbpJ still functions in the adult Ptf1a complex, to maintain acinar cell differentiation, as 
deletion of RbpL does not cause a dramatic acinar cell phenotype (Masui et al., 2010).  
The absence of RbpJ in the Ptf1a complex could, therefore, impact the differentiation 
status of acinar cells and make them susceptible to Kras-induced tumorigenesis.  In the 
future, it will be important to determine which scenario is the reason for increased Kras-
driven PanIN formation    
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We directly tested the hypothesis that impairing the function of the Ptf1a complex 
could make acinar cells susceptible to activated Kras by deleting Ptf1a itself.  Ptf1a bind 
to essentially all acinar specific promoters and is thought to be master regulator of acinar 
cell fate (Rose et al., 2001).  We found that, indeed, Ptf1a-deficient acinar cells were 
highly susceptible to activated Kras, showing that perturbing acinar cell differentiation 
promotes Kras-driven PanIN formation.  In examining pancreata expressing Rosa26NIC, 
we found that Ptf1a and other acinar-specific genes were downregulated, regardless of 
KrasG12D expression.  We further showed, using in vitro luciferase assays that active 
Notch and its target gene Hes1 inhibit activity of a Ptf1a based reporter plasmid.  While 
this suggests that Hes1 inhibits Ptf1a expression and is the mediator of active Notch 
signaling, these results are complicated by the fact that the Ptf1a complex autoregulates 
Ptf1a expression.  Hes1 therefore could be inhibiting Ptf1a complex function at the level 
of protein-protein interaction, which would result in reduced Ptf1a expression (Esni et al., 
2004; Ghosh and Leach, 2006).  The mechanism remains unclear but these results 
suggest that Hes1 may play a critical role in tumorigenesis.  Therefore, the synergy 
between Notch and Kras may not be a convergence of the two pathways on key 
oncogenic targets, but instead through the downregulation of Ptf1a and perturbation of 
acinar cell differentiation by Notch, which then allows KrasG12D to transform the cell. 
Hes1 is expressed by human and mouse PanINs and PDAC (Hingorani et al., 
2003; Miyamoto et al., 2003), which led to the hypothesis that Notch signaling is active 
in these lesions.  Hes1, however, is now known to be upregulated by Notch independent 
pathways (Ingram et al., 2008).  We found that Hes1 was upregulated following 
transgenic Notch activation and deletion RbpJ.  It is therefore possible that in human 
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PanINs Hes1 is upregulated in a Notch independent manner.  In our hands, PanIN 
formation is always accompanied by upregulation of Hes1, and future studies should 
further scrutinize the regulation of Hes1 and its role in pancreatic tumorigenesis.   
One physiological situation in which acinar cell differentiation is perturbed, 
Notch signaling is active, and Hes1 is upregulated is following pancreatic injury (Jensen 
et al., 2005).  If perturbation of acinar cell differentiation were sufficient to allow for 
activated Kras to drive PanIN formation then, cells expressing KrasG12D would rapidly 
give rise to PanINs following injury.  This is exactly what we observed following 
experimental acute pancreatitis induced in pancreata expressing acinar restricted 
KrasG12D.  As only about half the acinar cells express KrasG12D using ElaCreERT, this 
phenotype is much more severe in Pdx1Cre; KrasLSL-G12D pancreata in which nearly all 
cells are expressing KrasG12D (data not shown).   
Together these results provide a model for human pancreatic tumorigenesis that 
begins with spontaneous activating Kras mutation in a differentiated adult acinar cell 
(Fig, 6.1).  This mutated cell remains a functional acinar cell and perhaps divides and 
gives rise to more mutant acinar cells over the course of life.  It is not until the 
differentiation status of that acinar cell is affected, possibly following acute injury or a 
simple local inflammatory event that is undetectable clinically, that tumorigenesis is 
initiated.  We hypothesize that even in “uninjured” KrasG12D-expressing mouse pancreata, 
PanIN initiation is triggered by local spontaneous inflammation events.  The presence of 
small areas of ADM in normal pancreatic tissue that does not harbor activated Kras 
mutations (Shi et al., 2009) supports the notion that ADM can be spontaneously triggered 
on a small scale in normal tissue. 
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We know that loss of Ptf1a sensitizes acinar cells to activated Kras, that active 
Notch can downregulate Ptf1a and promote Kras-driven tumorigenesis, and that acute 
pancreatitis can trigger KrasG12D expressing cells to initiate tumorigenesis.  If it turns out 
that the increased PanIN phenotype we saw in RbpJ deficient pancreata is due to its 
absence in the Ptf1a complex thus affecting the differentiation status of the cell, we will 
have provided four lines of evidence that the differentiation status of an acinar cell 
dictates its transformability by mutant Kras.  Our results also demonstrate that 
inflammation provides a ripe environment for tumorigenesis, potentially explaining why 
chronic pancreatitis is the leading risk factor to developing pancreatic cancer.  It is our 
hope that the work presented here will provide another stepping-stone towards a goal of 
better early detection diagnostics and more efficacious therapies to help combat this 










Figure 6.1:  Model of acinar derived Kras-driven PanIN formation.  We hypothesize 
that acinar cells serve as the origin of PDAC and that they can give rise to duct-like 
PanIN lesions by undergoing ADM.  We further hypothesize that an activated-Kras 
expressing cell will remain normal until an insult occurs that activates Notch signaling 
and decreases Ptf1a expression.  Reduced Ptf1a expression perturbs acinar cell 
differentiation, which may create a permissive cellular environment for Kras to drive 
tumorigenesis.  One such insult may be a local inflammatory event, which would cause 
ADM that under normal circumstances would resolve with the redifferentiation of acinar 
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